0001193125-15-237157.txt : 20150728 0001193125-15-237157.hdr.sgml : 20150728 20150626162059 ACCESSION NUMBER: 0001193125-15-237157 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20150626 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PIERIS PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001583648 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 300784346 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: LISE-MEITNER-STRASSE 30 CITY: FREISING-WEIHENSTEPHAN STATE: 2M ZIP: 85354 BUSINESS PHONE: 49 81 6114 11400 MAIL ADDRESS: STREET 1: LISE-MEITNER-STRASSE 30 CITY: FREISING-WEIHENSTEPHAN STATE: 2M ZIP: 85354 FORMER COMPANY: FORMER CONFORMED NAME: Marika Inc. DATE OF NAME CHANGE: 20130805 CORRESP 1 filename1.htm Acceleration Request

June 26, 2015

U.S. Securities and Exchange Commission

Division of Corporation Finance

101 F Street NE Mailstop 4720

Washington, D.C. 20549

Attention: Jeffrey P. Riedler

                  Assistant Director

 

  Re: Pieris Pharmaceuticals, Inc.
       Registration Statement on Form S-1 (File No. 333-204833)

Ladies and Gentlemen:

In connection with the above-captioned Registration Statement, we, the representatives of the several underwriters, wish to advise you that between June 17, 2015 and June 25, 2015, approximately 1,379 copies of the Preliminary Prospectus dated June 17, 2015 were distributed as follows:

 

  •   10 to prospective underwriters and dealers;

 

  •   487 to institutional investors; and

 

  •   882 to individuals.

The undersigned, as representatives of the several underwriters, have and will, and each underwriter and dealer has advised the undersigned that it has and will, comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.

Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, we hereby join in the request of the registrant that the effectiveness of the above-captioned Registration Statement, as amended, be accelerated to 9:00 a.m., Washington, D.C. time, on June 29, 2015 or as soon thereafter as practicable.

[Signature page follows]

Very truly yours,

OPPENHEIMER & CO. INC.

JMP SECURITIES LLC

As representatives of the

several Underwriters

 

OPPENHEIMER & CO. INC.

By:

/s/ Douglas Cameron

Name:

 Douglas Cameron

Title:

 Head of Equity Capital Markets
JMP SECURITIES LLC

By:

/s/ Stephen Ortiz

Name: Stephen Ortiz
Title: Managing Director

 

cc:

 Stephen S. Yoder, Pieris Pharmaceuticals, Inc.
Darlene Deptula-Hicks, Pieris Pharmaceuticals, Inc.
William C. Hicks, Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
Marc Mantell, Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
Thomas Levato, Goodwin Procter LLP

[Signature Page to Underwriters’ Acceleration Request Letter]